NEW YORK (TheStreet) -- Shares of NeoStem (NBS) plummeted 25.52% to $5.05 in late morning trading Tuesday after the biotech company announced poor results from a trial of its proprietary cardiac stem-cell therapy NBS10.
NBS10, which used to be called AMR-001, missed two primary endpoints in the study to test the therapy's efficacy. The stem-cell therapy comes from a patient's own bone marrow and is injected into patients after a heart attack. The stem cells are then supposed to help blood flow and build cardiac muscle.
NeoStem's trial used non-invasive imaging to monitor blood flow through the heart six months after a one dose of NBS10 or a placebo. The study showed no difference between NBS and placebo, NeoStem said.
The company announced the data at the American Heart Association annual meeting on Monday.
For more on this story, read TheStreet's Adam Feuerstein's in-depth coverage here.NBS data by YCharts